{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:51:27Z","timestamp":1792813887275,"version":"4.5.0"},"reference-count":117,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,4,21]]},"DOI":"10.2967\/jnumed.124.268071","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T14:00:15Z","timestamp":1749132015000},"page":"jnumed.124.268071","source":"Crossref","is-referenced-by-count":11,"title":["Treatment Response Evaluation in Prostate Cancer Using PSMA PET\/CT"],"prefix":"10.2967","author":[{"given":"Andrei","family":"Gafita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ceci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge D.","family":"Oldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir H.","family":"Khandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic E.","family":"Lecouvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilja B.","family":"Solnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"2025060511000589000_jnumed.124.268071v1.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"2025060511000589000_jnumed.124.268071v1.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21442"},{"key":"2025060511000589000_jnumed.124.268071v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.06.010"},{"key":"2025060511000589000_jnumed.124.268071v1.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2025060511000589000_jnumed.124.268071v1.5","doi-asserted-by":"crossref","unstructured":"Hennrich U Eder M . [68Ga]Ga-PSMA-11: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer. Pharmaceuticals (Basel). 2021;14.","DOI":"10.3390\/ph14080713"},{"key":"2025060511000589000_jnumed.124.268071v1.6","unstructured":"FDA approves second PSMA-targeted PET imaging drug for men with prostate cancer. U.S. Food and Drug Administration website. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer. Published May 27, 2021. Accessed February 21, 2024."},{"key":"2025060511000589000_jnumed.124.268071v1.7","unstructured":"FDA approves first PSMA-targeted PET imaging drug for men with prostate cancer. U.S. Food and Drug Administration website. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer. Published December 1, 2020. Accessed Feburary 21, 2024."},{"key":"2025060511000589000_jnumed.124.268071v1.8","unstructured":"Drug Trials Snapshot: POSLUMA. U.S. Food and Drug Administration website. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshot-posluma. Published January 16, 2024. Accessed February 21, 2024."},{"key":"2025060511000589000_jnumed.124.268071v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"2025060511000589000_jnumed.124.268071v1.10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cpet.2024.03.009","article-title":"Treatment response imaging in prostate cancer","volume":"19","author":"Swiha","year":"2024","journal-title":"PET Clin."},{"key":"2025060511000589000_jnumed.124.268071v1.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263072"},{"key":"2025060511000589000_jnumed.124.268071v1.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233817"},{"key":"2025060511000589000_jnumed.124.268071v1.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265874"},{"key":"2025060511000589000_jnumed.124.268071v1.14","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2967\/jnumed.120.259069","article-title":"Prospective, single-arm trial evaluating changes in uptake patterns on prostate-specific membrane antigen\u2013targeted 18F-DCFPyL PET\/CT in patients with castration-resistant prostate cancer starting abiraterone or enzalutamide","volume":"62","author":"Zukotynski","year":"2021","journal-title":"J Nucl Med."},{"key":"2025060511000589000_jnumed.124.268071v1.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263006"},{"key":"2025060511000589000_jnumed.124.268071v1.16","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1097\/MNM.0000000000001446","article-title":"Evaluation of [68Ga]Ga-PSMA PET\/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survival","volume":"42","author":"Kurth","year":"2021","journal-title":"Nucl Med Commun."},{"key":"2025060511000589000_jnumed.124.268071v1.17","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060511000589000_jnumed.124.268071v1.18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060511000589000_jnumed.124.268071v1.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223099"},{"key":"2025060511000589000_jnumed.124.268071v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.09.003"},{"key":"2025060511000589000_jnumed.124.268071v1.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.260455"},{"key":"2025060511000589000_jnumed.124.268071v1.22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1148\/radiol.2021202771","article-title":"Prostate-specific membrane antigen PET in prostate cancer","volume":"299","author":"Lawhn-Heath","year":"2021","journal-title":"Radiology."},{"key":"2025060511000589000_jnumed.124.268071v1.23","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-016-0957-6"},{"key":"2025060511000589000_jnumed.124.268071v1.24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev-med-062117-073027","article-title":"Imaging of prostate-specific membrane antigen with small-molecule PET radiotracers: from the bench to advanced clinical applications","volume":"70","author":"Rowe","year":"2019","journal-title":"Annu Rev Med."},{"key":"2025060511000589000_jnumed.124.268071v1.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219501"},{"key":"2025060511000589000_jnumed.124.268071v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.01.049"},{"key":"2025060511000589000_jnumed.124.268071v1.27","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA. Oncol."},{"key":"2025060511000589000_jnumed.124.268071v1.28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bju.14506","article-title":"Gallium-68-prostate-specific membrane antigen (68Ga-PSMA) positron emission tomography (PET)\/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer","volume":"124","author":"van Leeuwen","year":"2019","journal-title":"BJU Int."},{"key":"2025060511000589000_jnumed.124.268071v1.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.203877"},{"key":"2025060511000589000_jnumed.124.268071v1.30","doi-asserted-by":"publisher","DOI":"10.1155\/JBB.2005.287"},{"key":"2025060511000589000_jnumed.124.268071v1.31","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3390\/cancers15010247","article-title":"The impact of PSMA-PET on oncologic control in prostate cancer patients who experienced psa persistence or recurrence","volume":"15","author":"Bianchi","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2025060511000589000_jnumed.124.268071v1.32","doi-asserted-by":"crossref","unstructured":"Hofman MS Kasivisvanathan V Link E . Baseline nodal status on 68Ga-PSMA-11 positron emission tomography\/computed tomography in men with intermediate- to high-risk prostate cancer is prognostic for treatment failure: follow-up of the proPSMA trial. Eur Urol Oncol. November 28, 2024 [Epub ahead of print].","DOI":"10.1016\/j.euo.2024.11.006"},{"key":"2025060511000589000_jnumed.124.268071v1.33","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate."},{"key":"2025060511000589000_jnumed.124.268071v1.34","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s12094-024-03625-y","article-title":"PSMA PET\/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"27","author":"Henr\u00edquez","year":"2025","journal-title":"Clin Transl Oncol."},{"key":"2025060511000589000_jnumed.124.268071v1.35","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA. Oncol."},{"key":"2025060511000589000_jnumed.124.268071v1.36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00605-2"},{"key":"2025060511000589000_jnumed.124.268071v1.37","unstructured":"Hofman MS Emmett L Sandhu S . Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2023."},{"key":"2025060511000589000_jnumed.124.268071v1.38","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264104"},{"key":"2025060511000589000_jnumed.124.268071v1.39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3390\/cancers14010149","article-title":"Early PSA change after [177Lu]PSMA-617 radioligand therapy as a predicator of biochemical response and overall survival","volume":"14","author":"Kind","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2025060511000589000_jnumed.124.268071v1.40","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1158\/1078-0432.CCR-23-1043","article-title":"Circulating tumor DNA biomarkers for response assessment in prostate cancer","volume":"29","author":"Sartor","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2025060511000589000_jnumed.124.268071v1.41","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol."},{"key":"2025060511000589000_jnumed.124.268071v1.42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","article-title":"Prostate-specific membrane antigen reporting and data system version 2.0","volume":"84","author":"Werner","year":"2023","journal-title":"Eur Urol."},{"key":"2025060511000589000_jnumed.124.268071v1.43","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060511000589000_jnumed.124.268071v1.44","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000000592"},{"key":"2025060511000589000_jnumed.124.268071v1.45","doi-asserted-by":"publisher","DOI":"10.1007\/s00256-014-1903-9"},{"key":"2025060511000589000_jnumed.124.268071v1.46","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30571-0"},{"key":"2025060511000589000_jnumed.124.268071v1.47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0815"},{"key":"2025060511000589000_jnumed.124.268071v1.48","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.euf.2016.06.018","article-title":"Rationale for modernising imaging in advanced prostate cancer","volume":"3","author":"Padhani","year":"2017","journal-title":"Eur Urol Focus."},{"key":"2025060511000589000_jnumed.124.268071v1.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2007.05.022"},{"key":"2025060511000589000_jnumed.124.268071v1.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025060511000589000_jnumed.124.268071v1.51","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/annonc\/mdw180","article-title":"Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","volume":"30","author":"Gillessen","year":"2019","journal-title":"Ann Oncol."},{"key":"2025060511000589000_jnumed.124.268071v1.52","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307"},{"key":"2025060511000589000_jnumed.124.268071v1.53","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0","volume":"280","author":"O","year":"2016","journal-title":"Radiology."},{"key":"2025060511000589000_jnumed.124.268071v1.54","doi-asserted-by":"crossref","unstructured":"Burger IA Beets-Tan RGH . Therapy monitoring of oncologic disease in the abdomen (including PET\/CT). In: Hodler J Kubik-Huch RA von Schulthess GK , eds. Diseases of the Abdomen and Pelvis 2018-2021: Diagnostic Imaging - IDKD Book. Springer; 2018:35\u201347.","DOI":"10.1007\/978-3-319-75019-4_4"},{"key":"2025060511000589000_jnumed.124.268071v1.55","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0226"},{"key":"2025060511000589000_jnumed.124.268071v1.56","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00259-024-06905-5","article-title":"Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer","volume":"52","author":"Santo","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060511000589000_jnumed.124.268071v1.57","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2967\/jnumed.119.236075","article-title":"Repeatability of quantitative 18F-DCFPyL PET\/CT measurements in metastatic prostate cancer","volume":"61","author":"Jansen","year":"2020","journal-title":"J Nucl Med."},{"key":"2025060511000589000_jnumed.124.268071v1.58","doi-asserted-by":"crossref","first-page":"7056983","DOI":"10.1155\/2022\/7056983","article-title":"High SUVs have more robust repeatability in patients with metastatic prostate cancer: results from a prospective test\u2013retest cohort imaged with 18F-DCFPyL","volume":"2022","author":"Werner","year":"2022","journal-title":"Mol Imaging."},{"key":"2025060511000589000_jnumed.124.268071v1.59","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3390\/diagnostics11061100","article-title":"Evaluation of quantitative Ga-68 PSMA PET\/CT repeatability of recurrent prostate cancer lesions using both OSEM and Bayesian penalized likelihood reconstruction algorithms","volume":"11","author":"Roef","year":"2021","journal-title":"Diagnostics (Basel)."},{"key":"2025060511000589000_jnumed.124.268071v1.60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00259-016-3481-7","article-title":"177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment","volume":"44","author":"Yadav","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060511000589000_jnumed.124.268071v1.61","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s12149-019-01376-3","article-title":"The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival","volume":"33","author":"Acar","year":"2019","journal-title":"Ann Nucl Med."},{"key":"2025060511000589000_jnumed.124.268071v1.62","doi-asserted-by":"publisher","DOI":"10.7150\/thno.48107"},{"key":"2025060511000589000_jnumed.124.268071v1.63","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.189050"},{"key":"2025060511000589000_jnumed.124.268071v1.64","doi-asserted-by":"crossref","first-page":"100218","DOI":"10.1016\/j.jbo.2019.100218","article-title":"Local control and vertebral compression fractures following stereotactic body radiotherapy for spine metastases","volume":"15","author":"Ozdemir","year":"2019","journal-title":"J Bone Oncol."},{"key":"2025060511000589000_jnumed.124.268071v1.65","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1007\/s00259-019-4258-6","article-title":"68Ga-PSMA PET\/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"46","author":"Heinzel","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060511000589000_jnumed.124.268071v1.66","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s00259-017-3887-x","article-title":"Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET\/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy","volume":"45","author":"Seitz","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060511000589000_jnumed.124.268071v1.67","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s00259-020-05165-3","article-title":"18F-PSMA-1007 PET\/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results","volume":"48","author":"Mittlmeier","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060511000589000_jnumed.124.268071v1.68","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3390\/biom11081099","article-title":"Response assessment and prediction of progression-free survival by 68Ga-PSMA-11 PET\/CT based on tumor-to-liver ratio (TLR) in patients with mCRPC undergoing 177Lu-PSMA-617 radioligand therapy","volume":"11","author":"Khreish","year":"2021","journal-title":"Biomolecules."},{"key":"2025060511000589000_jnumed.124.268071v1.69","doi-asserted-by":"publisher","DOI":"10.7150\/thno.56211"},{"key":"2025060511000589000_jnumed.124.268071v1.70","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","article-title":"Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer","volume":"46","author":"Grubmuller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060511000589000_jnumed.124.268071v1.71","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s13139-018-0548-3","article-title":"Evaluation of RECIST, PERCIST, EORTC, and MDA criteria for assessing treatment response with Ga68-PSMA PET-CT in metastatic prostate cancer patient with biochemical progression: a comparative study","volume":"52","author":"Gupta","year":"2018","journal-title":"Nucl Med Mol Imaging."},{"key":"2025060511000589000_jnumed.124.268071v1.72","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4103\/UA.UA_111_18","article-title":"Evaluation of response in patients of metastatic castration resistant prostate cancer undergoing systemic radiotherapy with lutetium177-prostate-specific membrane antigen: a comparison between response evaluation criteria in solid tumors, positron-emission tomography response criteria in solid tumors, European organization for research and treatment of cancer, and MDA criteria assessed by gallium 68-prostate-specific membrane antigen positron-emission tomography-computed tomography","volume":"11","author":"Gupta","year":"2019","journal-title":"Urol Ann."},{"key":"2025060511000589000_jnumed.124.268071v1.73","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/pros.23919","article-title":"Response assessment using [68Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer","volume":"80","author":"Grubmuller","year":"2020","journal-title":"Prostate."},{"key":"2025060511000589000_jnumed.124.268071v1.74","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s00259-022-06047-6","article-title":"Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET\/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study","volume":"50","author":"Ke","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060511000589000_jnumed.124.268071v1.75","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3390\/jcm9051390","article-title":"Metabolic tumour volume from PSMA PET\/CT scans of prostate cancer patients during chemotherapy: do different software solutions deliver comparable results?","volume":"9","author":"Hartrampf","year":"2020","journal-title":"J Clin Med."},{"key":"2025060511000589000_jnumed.124.268071v1.76","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.260836"},{"key":"2025060511000589000_jnumed.124.268071v1.77","doi-asserted-by":"crossref","first-page":"e222148","DOI":"10.1148\/radiol.222148","article-title":"Response Evaluation Criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology."},{"key":"2025060511000589000_jnumed.124.268071v1.78","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1007\/s00259-023-06382-2","article-title":"Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [68Ga]Ga-PSMA-11 PET images","volume":"50","author":"Kendrick","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060511000589000_jnumed.124.268071v1.79","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12149-024-01990-w","article-title":"Evaluating response to radium-223 using 68Ga-PSMA PET\/CT imaging in patients with metastatic castration-resistant prostate cancer","volume":"39","author":"Shagera","year":"2025","journal-title":"Ann Nucl Med."},{"key":"2025060511000589000_jnumed.124.268071v1.80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025060511000589000_jnumed.124.268071v1.81","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04485-3"},{"key":"2025060511000589000_jnumed.124.268071v1.82","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265155"},{"key":"2025060511000589000_jnumed.124.268071v1.83","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","article-title":"Radiation dosimetry in 177Lu-PSMA-617 therapy","volume":"52","author":"Jackson","year":"2022","journal-title":"Semin Nucl Med."},{"key":"2025060511000589000_jnumed.124.268071v1.84","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264677"},{"key":"2025060511000589000_jnumed.124.268071v1.85","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1007\/s00259-024-06718-6","article-title":"Same-day post-therapy imaging with a new generation whole-body digital SPECT\/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer","volume":"51","author":"Song","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060511000589000_jnumed.124.268071v1.86","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00259-023-06536-2","article-title":"Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT\/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study","volume":"51","author":"Neubauer","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060511000589000_jnumed.124.268071v1.87","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41585-022-00618-w","article-title":"The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer","volume":"19","author":"Wang","year":"2022","journal-title":"Nat Rev Urol."},{"key":"2025060511000589000_jnumed.124.268071v1.88","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00256-019-03230-z","article-title":"Comparison of PSMA-PET\/CT, choline-PET\/CT, NaF-PET\/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis","volume":"48","author":"Zhou","year":"2019","journal-title":"Skeletal Radiol."},{"key":"2025060511000589000_jnumed.124.268071v1.89","doi-asserted-by":"crossref","first-page":"7564","DOI":"10.1007\/s00330-024-10864-8","article-title":"Evaluating prostate cancer bone metastases response with whole-body MRI: what we know and still need to know","volume":"34","author":"Padhani","year":"2024","journal-title":"Eur Radiol."},{"key":"2025060511000589000_jnumed.124.268071v1.90","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/jmri.27485","article-title":"Whole-body magnetic resonance imaging for prostate cancer assessment: current status and future directions","volume":"55","author":"Van Nieuwenhove","year":"2022","journal-title":"J Magn Reson Imaging."},{"key":"2025060511000589000_jnumed.124.268071v1.91","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.02.020"},{"key":"2025060511000589000_jnumed.124.268071v1.92","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.3390\/cancers13215286","article-title":"Comparison of 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography computed tomography (PET-CT) and whole-body magnetic resonance imaging (WB-MRI) with diffusion sequences (DWI) in the staging of advanced prostate cancer","volume":"13","author":"Van Damme","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2025060511000589000_jnumed.124.268071v1.93","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20280"},{"key":"2025060511000589000_jnumed.124.268071v1.94","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s00256-024-04723-2","article-title":"Present and future of whole-body MRI in metastatic disease and myeloma: how and why you will do it","volume":"53","author":"Lecouvet","year":"2024","journal-title":"Skeletal Radiol."},{"key":"2025060511000589000_jnumed.124.268071v1.95","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.05.033"},{"key":"2025060511000589000_jnumed.124.268071v1.96","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.07.002"},{"key":"2025060511000589000_jnumed.124.268071v1.97","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3177-4"},{"key":"2025060511000589000_jnumed.124.268071v1.98","doi-asserted-by":"crossref","unstructured":"Van Damme J Tombal B Michoux N . Value of whole-body magnetic resonance imaging using the MET-RADS-P criteria for assessing the response to intensified androgen deprivation therapy in metastatic hormone-na\u00efve and castration-resistant prostate cancer. Eur Urol Oncol. November 5, 2024 [Epub ahead of print].","DOI":"10.1016\/j.euo.2024.10.009"},{"key":"2025060511000589000_jnumed.124.268071v1.99","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.7270"},{"key":"2025060511000589000_jnumed.124.268071v1.100","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1106383108"},{"key":"2025060511000589000_jnumed.124.268071v1.101","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.181800"},{"key":"2025060511000589000_jnumed.124.268071v1.102","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","article-title":"Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer","volume":"1","author":"Aggarwal","year":"2018","journal-title":"Eur Urol Oncol."},{"key":"2025060511000589000_jnumed.124.268071v1.103","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.259226"},{"key":"2025060511000589000_jnumed.124.268071v1.104","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"2025060511000589000_jnumed.124.268071v1.105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1200\/JCO.2024.42.4_suppl.35","article-title":"PSMA PET imaging for evaluation of recurrent or persistent prostate cancer after primary prostate radiation","volume":"42","author":"Bennett","year":"2024","journal-title":"Journal of Clinical Oncology."},{"key":"2025060511000589000_jnumed.124.268071v1.106","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12149-019-01340-1","article-title":"Clinicopathological predictors of positive 68Ga-PSMA-11 PET\/CT in PSA-only recurrence of localized prostate cancer following definitive therapy","volume":"33","author":"Aydin","year":"2019","journal-title":"Ann Nucl Med."},{"key":"2025060511000589000_jnumed.124.268071v1.107","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00259-020-04945-1","article-title":"False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial","volume":"48","author":"Fendler","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060511000589000_jnumed.124.268071v1.108","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0360-3016(00)00637-4","article-title":"Postradiotherapy prostate biopsies: what do they really mean\u2014results for 498 patients","volume":"48","author":"Crook","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2025060511000589000_jnumed.124.268071v1.109","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/JU.0000000000000110","article-title":"Long-term implications of a positive posttreatment biopsy in patients treated with external beam radiotherapy for clinically localized prostate cancer","volume":"201","author":"Zelefsky","year":"2019","journal-title":"J Urol."},{"key":"2025060511000589000_jnumed.124.268071v1.110","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24020"},{"key":"2025060511000589000_jnumed.124.268071v1.111","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2020.07.014","article-title":"Interim results of a prospective prostate-specific membrane antigen-directed focal stereotactic reirradiation trial for locally recurrent prostate cancer","volume":"108","author":"Bergamin","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2025060511000589000_jnumed.124.268071v1.112","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266005"},{"key":"2025060511000589000_jnumed.124.268071v1.113","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268608"},{"key":"2025060511000589000_jnumed.124.268071v1.114","doi-asserted-by":"crossref","unstructured":"Ballinger JR Koziorowski J . Regulation of PET radiopharmaceuticals production in Europe. In: Khalil MM , ed. Basic Science of PET Imaging. Springer International Publishing; 2017:127\u2013143.","DOI":"10.1007\/978-3-319-40070-9_6"},{"key":"2025060511000589000_jnumed.124.268071v1.115","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267048"},{"key":"2025060511000589000_jnumed.124.268071v1.116","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13550-022-00948-1","article-title":"Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET","volume":"12","author":"Leung","year":"2022","journal-title":"EJNMMI Res."},{"key":"2025060511000589000_jnumed.124.268071v1.117","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1007\/s10278-024-01104-y","article-title":"An automated deep learning-based framework for uptake segmentation and classification on PSMA PET\/CT imaging of patients with prostate cancer","volume":"37","author":"Li","year":"2024","journal-title":"J Imaging Inform Med."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T14:00:26Z","timestamp":1749132026000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":117,"alternative-id":["10.2967\/jnumed.124.268071"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268071","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]}}}